(25):2406?5. [PubMed: 21082868] 65. Krauss RM, Wojnooski K, Orr J, et al. Modifications in lipoprotein subfraction concentration and composition in healthier people treated together with the CETP inhibitor anacetrapib. J Lipid Res. 2012 Mar; 53(three):540?. [PubMed: 22180633]NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author ManuscriptClin Pharmacokinet. Author manuscript; offered in PMC 2014 August 01.Mohammadpour and AkhlaghiPage66. Lamarche B, Tchernof A, Moorjani S, et al. Smaller, dense low-density lipoprotein particles as a predictor with the threat of ischemic heart disease in men. Prospective results in the Quebec Cardiovascular Study. Circulation. 1997 Jan 7; 95(1):69?5. [PubMed: 8994419] 67. Fernandez MC, Escribano A, Mateo AI, et al. Design and style, synthesis and structure-activity-relationship of 1,5-tetrahydronaphthyridines as CETP inhibitors. Bioorg Med Chem Lett. 2012 Could 1; 22(9): 3056?2. [PubMed: 22497761] 68. Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects in the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA. 2011 Nov 16; 306(19):2099?09. [PubMed: 22089718] 69. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and danger of myocardial infarction: a mendelian randomisation study. Lancet. 2012 May perhaps 17. 70. Wilson PW, Abbott RD, Castelli WP. Higher density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis. 1988 Nov-Dec;8(six):737?1. [PubMed: 3196218] 71. Franceschini G, Sirtori CR, Capurso A 2nd, et al. A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with substantial lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest. 1980 Nov; 66(five):892?00. [PubMed: 7430351] 72. Calabresi L, Baldassarre D, Castelnuovo S, et al. Functional lecithin: cholesterol acyltransferase just isn’t expected for effective atheroprotection in humans. Circulation. 2009 Aug 18; 120(7):628?five. [PubMed: 19687369] 73. Frikke-Schmidt R, Nordestgaard BG, Stene MC, et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart illness.2-Aminobenzaldehyde structure JAMA.3-Bromo-5-fluoro-4-methylbenzoic acid Price 2008 Jun 4; 299(21):2524?two.PMID:23376608 [PubMed: 18523221] 74. Tall AR. Cholesterol efflux pathways and other possible mechanisms involved inside the atheroprotective impact of higher density lipoproteins. J Intern Med. 2008 Mar; 263(three):256?3. [PubMed: 18271871] 75. Linsel-Nitschke P, Jansen H, Aherrarhou Z, et al. Macrophage cholesterol efflux correlates with lipoprotein subclass distribution and risk of obstructive coronary artery disease in individuals undergoing coronary angiography. Lipids Overall health Dis. 2009; eight:14. [PubMed: 19348677] 76. Mikkola TS, Anthony MS, Clarkson TB, et al. Serum cholesterol efflux possible is an independent predictor of coronary artery atherosclerosis. Atherosclerosis. 2003 Sep; 170(1):31?. [PubMed: 12957680] 77. Low H, Hoang A, Sviridov D. Cholesterol efflux assay. J Vis Exp. 2012; (61):e3810. [PubMed: 22414908] 78. Daniil G, Phedonos AA, Holleboom AG, et al. Characterization of antioxidant/anti-inflammatory properties and apoA-I-containing subpopulations of HDL from family members subjects with monogenic low HDL problems. Clin Chim Acta. 2011 Jun 11; 412(13?4):1213?0. [PubMed: 21420943] 79. Bhattacharyya T, Nicholls SJ, Topol EJ, et al. Partnership of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic o.